Online citations, reference lists, and bibliographies.
← Back to Search

Obesity And The Metabolic Syndrome

P. Grandjean
Published 2012 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
This paper references
10.1038/414782a
Global and societal implications of the diabetes epidemic
P. Zimmet (2001)
10.1161/01.CIR.0000133317.49796.0E
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
S. Grundy (2004)
10.1007/BF02534017
Intercorrelations among plasma high density lipoprotein, obesity and triglycerides in a normal population
M. Albrink (2006)
10.1111/j.1749-6632.2010.05875.x
Adipokines as novel biomarkers and regulators of the metabolic syndrome
Yingfeng Deng (2010)
10.1016/J.METABOL.2003.10.032
Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals.
T. McLaughlin (2004)
10.1001/archinte.168.9.928
The impact of obesity on cardiovascular disease risk factors and subclinical vascular disease: the Multi-Ethnic Study of Atherosclerosis.
G. Burke (2008)
10.1016/0026-0495(85)90147-7
Evidence for a regional component of body fatness in the association with serum lipids in men and women.
J. Després (1985)
10.2337/DIACARE.28.11.2745
Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S.
E. Ford (2005)
10.1172/JCI111040
Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution.
M. Krotkiewski (1983)
10.1056/NEJMOA020194
Effects of the amount and intensity of exercise on plasma lipoproteins.
W. Kraus (2002)
10.2337/DIACARE.25.7.1198
Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia.
V. Athyros (2002)
10.1007/s00125-005-0125-z
Overproduction of large VLDL particles is driven by increased liver fat content in man
M. Adiels (2005)
10.1111/j.1749-6632.1965.tb34830.x
THE RELATIONSHIP BETWEEN SERUM TRIGLYCERIDES AND SKINFOLD THICKNESS IN OBESE SUBJECTS *
M. Albrink (1965)
10.3945/ajcn.2009.27908
Mediterranean-style dietary pattern, reduced risk of metabolic syndrome traits, and incidence in the Framingham Offspring Cohort.
M. Rumawas (2009)
10.1161/01.CIR.0000108926.04022.0C
Association of the Metabolic Syndrome With History of Myocardial Infarction and Stroke in the Third National Health and Nutrition Examination Survey
John K. Ninomiya (2004)
10.1111/j.1463-1326.2006.00590.x
Ectopic fat accumulation and metabolic syndrome
Neda Rasouli (2007)
10.1002/j.1550-8528.1996.tb00274.x
Immunoassay of endogenous plasma insulin in man.
R. Yalow (1960)
10.1089/dia.2008.0090
Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting.
R. Bhushan (2009)
10.1089/met.2008.0070
Health care utilization and costs by metabolic syndrome risk factors.
D. Boudreau (2009)
10.1016/S0140-6736(08)60602-9
Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies
N. Sattar (2008)
10.1016/S1262-3636(07)70146-5
Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials.
A. Scheen (2004)
10.1161/ATVBAHA.107.159228
Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk.
J. Després (2008)
10.7326/0003-4819-138-5-200303040-00012
Importance of Identifying the Overweight Patient Who Will Benefit the Most by Losing Weight
G. Reaven (2003)
10.1056/NEJMOA003417
Impact of High-Normal Blood Pressure on the Risk of Cardiovascular Disease
Ramachandran S. Vasan (2001)
10.1038/nature05488
Abdominal obesity and metabolic syndrome
J. Després (2006)
10.1007/3-540-27661-0_3
Metabolic syndrome: therapeutic considerations.
S. Grundy (2005)
10.1056/NEJM198708063170605
Insulin resistance in essential hypertension.
E. Ferrannini (1987)
10.1016/J.MCNA.2004.04.013
Pathogenesis of type 2 diabetes mellitus.
R. DeFronzo (2004)
10.1161/01.CIR.102.2.179
Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?
I. Lemieux (2000)
10.1111/j.1467-789X.2005.00221.x
Diagnosis and management of the metabolic syndrome in obesity
E. Liberopoulos (2005)
10.1161/CIRCULATIONAHA.105.539528
Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus
P. Wilson (2005)
10.1111/j.1751-7176.2009.00209.x
The Effects of Resistance Training on Metabolic Health With Weight Regain
Shana O. Warner (2010)
[Depression in the elderly. Clinical aspects].
D. Barbier (2001)
10.1056/NEJM200105033441801
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.
J. Tuomilehto (2001)
10.1161/HC5001.100624
Influence of Low High-Density Lipoprotein Cholesterol and Elevated Triglyceride on Coronary Heart Disease Events and Response to Simvastatin Therapy in 4S
C. Ballantyne (2001)
10.1210/JCEM-54-2-254
Relation of Body Fat Distribution to Metabolic Complications of Obesity
A. Kissebah (1982)
10.1001/ARCHINTE.167.10.1068
Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study.
P. Wilson (2007)
10.1001/ARCHINTE.160.8.1177
Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
J. Guyton (2000)
10.2337/DIACARE.25.5.829
The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study.
D. Dunstan (2002)
10.1586/14779072.2.2.213
Treatment of metabolic syndrome
A. Wagh (2004)
10.1111/j.1532-5415.2006.00974.x
Modifiable Lifestyle Factors and the Metabolic Syndrome in Older Men: Effects of Lifestyle Changes
S. Wannamethee (2006)
10.1001/JAMA.287.3.356
Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.
E. Ford (2002)
10.1056/NEJMOA020245
Obesity and the risk of heart failure.
H. Taegtmeyer (2002)
10.2337/DIACARE.27.2.538
Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort.
N. McKeown (2004)
10.1046/j.1467-789x.2000.00013.x
Redefining Type 2 diabetes: ‘Diabesity’ or ‘Obesity Dependent Diabetes Mellitus’?
A. Astrup (2000)
10.4239/wjd.v1.i3.76
Metabolic effects of obesity: A review.
Parul Singla (2010)
10.1001/JAMA.288.21.2709
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.
H. Lakka (2002)
10.2337/DIACARE.24.3.588
Recent advances in our understanding of insulin action and insulin resistance.
D. Le Roith (2001)
10.1016/S0002-9149(02)02749-2
Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity.
P. Kwiterovich (2002)
Obesity: assessment and management in primary care.
J. Lyznicki (2001)
10.1046/j.1365-2796.2001.00864.x
The dysmetabolic syndrome
L. Groop (2001)
10.1097/HCO.0b013e32833cd474
A practical approach to the metabolic syndrome: review of current concepts and management
R. Tota-Maharaj (2010)
10.1161/01.CIR.99.6.779
Mediterranean Diet, Traditional Risk Factors, and the Rate of Cardiovascular Complications After Myocardial Infarction Final Report of the Lyon Diet Heart Study
M. Lorgeril (1999)
10.1016/j.nut.2007.11.008
Lifestyle intervention in the management of metabolic syndrome: could we improve adherence issues?
E. Fappa (2008)
10.1161/01.CIR.0000136581.59584.0E
C-Reactive Protein, the Metabolic Syndrome, and Prediction of Cardiovascular Events in the Framingham Offspring Study
M. Rutter (2004)
10.2165/00007256-200434060-00004
What is the Relationship Between Exercise and Metabolic Abnormalities?
S. Carroll (2004)
10.3949/CCJM.74.3.199
Metabolic syndrome: controversial but useful.
M. Stolar (2007)
10.1097/00019048-200106000-00021
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).
S. Grundy (2001)
10.1161/01.STR.0000204354.06965.44
Metabolic Syndrome and the Risk of Stroke in Middle-Aged Men
S. Kurl (2006)
10.2337/DIACARE.26.3.861
Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic american indians: the Strong Heart Study.
H. Resnick (2003)
10.1016/S0140-6736(04)16895-5
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
H. Colhoun (2004)
10.1172/JCI7535
Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle.
K. Cusi (2000)
10.1136/bmj.289.6454.1257
Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden.
L. Lapidus (1984)
10.1111/j.1464-5491.2006.01858.x
Metabolic syndrome—a new world‐wide definition. A Consensus Statement from the International Diabetes Federation
K. Alberti (2006)
10.1001/ARCHSURG.139.10.1088
Effects of obesity surgery on the metabolic syndrome.
W. Lee (2004)
10.1161/01.CIR.0000080884.27358.49
Relationship of Metabolic Syndrome and Fibrinolytic Dysfunction to Cardiovascular Disease
Sonia S Anand (2003)
10.1001/jama.2009.2014
Prevalence and trends in obesity among US adults, 1999-2008.
K. Flegal (2010)
10.1016/S0021-9150(00)00514-1
Abdominal obesity is associated with accelerated progression of carotid atherosclerosis in men.
T. Lakka (2001)
10.2337/dc08-0423
Metabolic Syndrome and Incident Diabetes
E. Ford (2008)
10.7326/0003-4819-142-8-200504190-00009
The Effect of Metformin and Intensive Lifestyle Intervention on the Metabolic Syndrome: The Diabetes Prevention Program Randomized Trial
T. Orchard (2005)
10.4065/83.8.932
A practical "ABCDE" approach to the metabolic syndrome.
M. Blaha (2008)
10.1093/AJE/154.12.1150
Food patterns and components of the metabolic syndrome in men and women: a cross-sectional study within the Malmö Diet and Cancer cohort.
E. Wirfält (2001)
10.3132/dvdr.2004.010
The metabolic syndrome: one step forward, two steps back
S. Kim (2004)
10.1016/J.JACC.2005.12.046
Metabolic syndrome and the risk of cardiovascular disease in older adults.
J. Butler (2006)
10.1038/OBY.2004.174
Alcohol consumption and metabolic syndrome: does the type of beverage matter?
L. Djoussé (2004)
10.2337/DIACARE.27.7.1735
Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S).
K. Pyörälä (2004)
10.1111/j.1365-2796.2010.02325.x
The metabolic syndrome: time to get off the merry‐go‐round?
G. Reaven (2011)
10.2337/DIACARE.28.4.888
Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program.
R. Ratner (2005)
10.1161/CIRCULATIONAHA.109.192644
Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As
K. Alberti (2009)
10.1053/J.AJKD.2003.12.023
Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.
V. Athyros (2004)
10.2337/DIACARE.28.9.2289
The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.
R. Kahn (2005)
10.1097/01.hjr.0000114707.27531.48
The obesity epidemic, metabolic syndrome and future prevention strategies
P. James (2004)
10.1007/S00125-005-1695-5
Comment to: Borch-Johnsen K, Colagiuri S, Balkau B et al. (2004) Creating a pandemic of prediabetes: the proposed new diagnostic criteria for impaired fasting glycaemia. Diabetologia 47:1396-1402.
B. Balkau (2005)
10.1111/j.1753-0407.2010.00078.x
Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US *
E. Ford (2010)
10.2337/DIACARE.27.11.2707
Risk factors for the metabolic syndrome: the Coronary Artery Risk Development in Young Adults (CARDIA) study, 1985-2001.
M. Carnethon (2004)
10.2337/diacare.14.3.173
Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease
R. DeFronzo (1991)
10.1016/S0140-6736(66)92132-5
Serum-insulin in essential hypertension and in peripheral vascular disease.
T. Welborn (1966)
10.1161/CIRCULATIONAHA.107.185649
Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association.
W. Haskell (2007)
10.1016/J.AHJ.2004.07.013
Metabolic syndrome: definition, pathophysiology, and mechanisms.
P. J. Miranda (2005)
10.1007/s11892-011-0186-y
Perivascular Adipose Tissue and Its Role in Type 2 Diabetes and Cardiovascular Disease
R. Meijer (2011)
10.1093/EURHEARTJ/EHL524
The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns.
J. Wang (2007)
10.1172/JCI111776
Hyperinsulinemia. A link between hypertension obesity and glucose intolerance.
M. Modan (1985)
10.2165/00007256-200131150-00002
Blood Lipid and Lipoprotein Adaptations to Exercise
J. Durstine (2001)
10.1016/S0140-6736(05)67663-5
Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study
S. Yusuf (2005)
10.2337/DIACARE.27.11.2676
Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease?
M. Stern (2004)
10.7326/0003-4819-144-7-200604040-00011
Adiposity of the Heart*, Revisited
J. McGavock (2006)
10.1056/NEJMOA011090
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
B. Brown (2001)
10.1136/bmj.288.6428.1401
Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913.
B. Larsson (1984)
10.1093/ajcn/82.1.222S
Long-term weight loss maintenance.
R. Wing (2005)
10.1007/BF01544100
Associazione di iperlipemia, diabete mellito e obesita' di medio grado
P. Avogaro (2005)
10.1161/CIRCULATIONAHA.108.772822
Aerobic Interval Training Versus Continuous Moderate Exercise as a Treatment for the Metabolic Syndrome: A Pilot Study
A. E. Tjønna (2008)
10.1097/HPC.0B013E318057D4C9
Cardiovascular disease under the influence of excess visceral fat.
J. Després (2007)
10.1001/ARCHINTE.165.22.2644
Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus.
S. Wannamethee (2005)
10.1161/01.CIR.97.18.1837
Prediction of coronary heart disease using risk factor categories.
P. Wilson (1998)
10.2165/11531380-000000000-00000
Resistance Training in the Treatment of the Metabolic Syndrome
B. Strasser (2010)
Targets for Intervention in Dyslipidemia in Diabetes
Gerald H. Tomkin (2008)
10.1007/s00125-005-0063-9
Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes
R. Guzder (2005)
10.1111/j.1467-789X.2004.00127.x
Effects of weight loss in overweight/obese individuals and long‐term lipid outcomes – a systematic review
A. Poobalan (2004)
10.1097/00005792-198205000-00001
The Pathogenesis of Non‐Insulin-Dependent Diabetes: AN UPDATE
R. DeFronzo (1982)
10.1001/archinte.168.15.1609
Identification and characterization of metabolically benign obesity in humans.
N. Stefan (2008)
10.1161/ATVBAHA.107.151092
Metabolic Syndrome Pandemic
S. Grundy (2008)
10.1042/CS20070115
Alterations in plasma and tissue lipids associated with obesity and metabolic syndrome.
C. Aguilera (2008)
10.3132/dvdr.2009.006
Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial
M. Hanefeld (2009)
10.1046/j.1464-5491.1999.00059.x
Comment on the provisional report from the WHO consultation
B. Balkau (1999)
10.1042/CS20050207
Physical activity, fitness and cardiovascular disease risk in adults: interactions with insulin resistance and obesity.
J. Gill (2006)
10.1152/japplphysiol.01361.2009
Exercise and the metabolic syndrome with weight regain.
T. Thomas (2010)
10.7326/0003-4819-140-6-200403160-00011
Effect of Alcohol Consumption on Diabetes Mellitus
A. Howard (2004)
10.1001/jama.2010.1950
Reexamining the physical examination for obese patients.
A. Silk (2011)
10.3810/PSM.2009.04.1678
Independent and Combined Effects of Aerobic Exercise and Pharmacological Strategies on Serum Triglyceride Concentrations: A Qualitative Review
E. Plaisance (2009)
10.1249/01.mss.0000115224.88514.3a
American College of Sports Medicine position stand. Exercise and hypertension.
L. Pescatello (2004)
10.2337/DIACARE.28.2.385
The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study.
A. McNeill (2005)
10.1056/NEJM197801052980101
Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients.
E. Reisin (1978)
10.1161/CIRCULATIONAHA.105.169404
Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
S. Grundy (2005)
10.2337/DIACARE.27.10.2444
Increasing prevalence of the metabolic syndrome among u.s. Adults.
E. Ford (2004)
10.1001/ARCHINTE.163.4.427
The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994.
Yongwoo Park (2003)
10.1016/0026-0495(94)90259-3
Impact of exercise intensity on body fatness and skeletal muscle metabolism.
A. Tremblay (1994)
10.1016/j.pcad.2009.12.004
Aldosterone: role in the cardiometabolic syndrome and resistant hypertension.
Adam T. Whaley-Connell (2010)
10.1093/AJCN/4.1.20
The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease.
J. Vague (1956)
10.1136/jcp.2003.012989
The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study
V. G. Athyros (2004)
10.1161/01.CIR.0000111245.75752.C6
Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition
S. Grundy (2004)
10.1056/NEJMOA012512
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
W. Knowler (2002)
10.1515/CCLM.2003.174
Diabesity: An Inflammatory Metabolic Condition
M. Schmidt (2003)
10.1001/JAMA.288.14.1723
Prevalence and trends in obesity among US adults, 1999-2000.
K. Flegal (2002)
10.1016/J.METABOL.2004.04.017
Lifestyle behaviors associated with lower risk of having the metabolic syndrome.
S. Zhu (2004)
10.1001/JAMA.291.23.2847
Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002.
Allison A. Hedley (2004)
10.1161/01.ATV.10.4.497
Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease.
J. Després (1990)
10.1152/ajpendo.00416.2010
Lipid-induced pancreatic β-cell dysfunction: focus on in vivo studies.
A. Giacca (2011)
10.1001/archinte.1989.00390070054005
The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension.
N. Kaplan (1989)
10.1161/CIRCULATIONAHA.109.887521
Impact of Body Mass Index and the Metabolic Syndrome on the Risk of Cardiovascular Disease and Death in Middle-Aged Men
J. Ärnlöv (2010)
10.1111/J.0889-7204.2005.04558.X
The Mediterranean diet: is it cardioprotective?
Marita C Bautista (2005)
10.7326/0003-4819-142-7-200504050-00011
Pharmacologic and Surgical Management of Obesity in Primary Care: A Clinical Practice Guideline from the American College of Physicians
V. Snow (2005)
10.1007/s11154-011-9168-2
Obesity-associated insulin resistance in skeletal muscle: Role of lipid accumulation and physical inactivity
K. Eckardt (2011)
10.2337/DIACARE.28.7.1769
Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence.
E. Ford (2005)
10.2337/DIACARE.28.9.2312
Inflammation, atherosclerosis, and aspects of insulin action.
Z. Bloomgarden (2005)
10.1249/MSS.0b013e3181949333
American College of Sports Medicine Position Stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults.
J. Donnelly (2009)
10.2337/DIACARE.28.7.1831
Metabolic syndrome: underrated or underdiagnosed?
K. Reynolds (2005)
10.1016/S0140-6736(08)60731-X
Metabolic syndrome—what is the clinical usefulness?
R. Kahn (2008)
10.1016/j.jacc.2010.05.034
The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis.
S. Mottillo (2010)
10.1016/J.JACC.2005.06.082
Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions.
K. Koh (2005)
10.1097/00000441-200512000-00004
Epidemiology of the Metabolic Syndrome
K. Reynolds (2005)
10.1038/nature05487
Mechanisms linking obesity with cardiovascular disease
L. Gaal (2006)
10.1111/j.1365-2796.2008.01935.x
The metabolic syndrome as a tool for predicting future diabetes: the AusDiab study
A. Cameron (2008)
10.1056/NEJMOA011161
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
B. Brenner (2001)
10.2337/DIACARE.26.12.3331
Lowering the criterion for impaired fasting glucose is in order.
S. Genuth (2003)
10.2337/DIACARE.28.7.1808
Rarer than a blue moon: the use of a diagnostic code for the metabolic syndrome in the U.S.
E. Ford (2005)
10.1161/01.CIR.0000080897.52664.94
Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study
N. Sattar (2003)
10.1016/S0002-9149(03)00111-5
Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.
G. Vega (2003)
10.1111/j.1471-0528.2006.01004.x
Review article: Is obesity an inflammatory illness? Role of low‐grade inflammation and macrophage infiltration in human white adipose tissue
R. Cancello (2006)
10.1001/archinte.168.15.1617
The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004).
R. Wildman (2008)
10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation
K. Alberti (1998)
10.1016/J.JACC.2006.09.032
Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies.
A. Gami (2007)
10.1038/oby.2009.382
The Utility of Physical Activity in the Management of Global Cardiometabolic Risk
P. Janiszewski (2009)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar